Torrent Pharmaceuticals Ltd. Stock price: Live updates

₹4516.2

0.26% (11.8)

Market Cap

₹1,52,915 Cr.

P/E

70.68

Key Ratios

Edit Ratio's

Market cap

1.53 L Cr

70.68

Prom Holding

68.31 %

ROE (%)

25.79

ROCE (%)

9.49

Div Yield (%)

0.84

Sales

13,979 Cr

OPM (%)

Debt to Equity

1.76

Institutions

25.24 %

Individual < 2 lac

2.75 %

No. of Shareholders

83,811

Edit Ratio's

About

Torrent Pharmaceuticals manufactures, develops, and markets generic pharmaceutical formulation… Read more

Low

3287

52W Range

High

4713

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New

Edit rows

Forensics

9 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

0 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Depreciation Effect

Depreciation accounting is not leading to increase in profits
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

ROE

Net profit margin is responsible for roe increase over last 10 years
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
Balance Sheet Strength

Balance sheet of the company is strong. it shouldnt have solvency or liquidity issues
Capex vs ROCE

Company has made significant capex which might be affecting its roce
Current vs Historic Valuation

Company is trading at a premium to 3yr historic valuations
Share price

Share price has increased over last 10 years but more due to rerating
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong

Market Share

3.16 %

(as of Jul 22)

Historic

Anti - Diabetes - Market Share

0.84 %

(as of Jul 22)

Historic

Anti-Infectives - Market Share

0.74 %

(as of Nov 21)

Historic

Anti-Malarial - Market Share

0.27 %

(as of Nov 21)

Historic

Antineo Plastic - Market Share

0.26 %

(as of Nov 21)

Historic

Blood Related - Market Share

7.22 %

(as of Jul 22)

Historic

Cardiovascular - Market Share

1.22 %

(as of Nov 21)

Historic

Dermatology - Market Share

0.01 %

(as of May 21)

Historic

Endocrinology - Market Share

4.93 %

(as of Jul 22)

Historic

Gastro-Intestinal - Market Share

1.50 %

(as of Nov 21)

Historic

Gynecology - Market Share

20 %

(as of Mar 19)

Source/Historic

Losartan & Lamtrigine - Market Share in Brazil

7.53 %

(as of Nov 21)

Historic

Neurological - Market Share

0.01 %

(as of Mar 18)

Historic

Ophthalmology - Market Share

3.05 %

(as of Nov 21)

Historic

Pain - Market Share

3.50 %

(as of Sep 24)

Historic

Pharmaceutical Sector - Market Share

0.19 %

(as of Nov 21)

Historic

Respiratory - Market Share

0 %

(as of Jul 22)

Historic

Sex Stimulants - Market Share

30 %

(as of Mar 19)

Source/Historic

Shelcal - Market Share

34.62 %

(as of May 19)

Historic

Stomatological - Market Share

0.40 %

(as of Nov 21)

Historic

Urology - Market Share

4.78 %

(as of Jul 22)

Historic

Vitamin & Dietary Supplements - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Therapeutic Area Break-Up

Acute vs Chronic

Asset Break-Up

Operational Metrics

Number of ANDA's Filed in USA (.)
Source
Number of ANDA's Approved By USFDA (.)
Source
Domestic Sales Growth - YoY (%)
Source
R&D as a % of Total Sales (%)
Source

Peer Comparison

Brands

Losar

Shelcal

Corporate Actions

Consolidated

DATE

DETAILS

Show Less

Suppliers

PSP Projects Ltd.
Aarti Drugs Ltd.
Gulshan Polyols Ltd.
Allcargo Gati Ltd. - (Amalgamated)
Sayaji Industries Ltd.

FAQs on Torrent Pharmaceuticals Ltd. Business

What does Torrent Pharma do?

Torrent Pharmaceuticals is engaged in manufacturing, developing and marketing of generic pharmaceutical formulations. The company is a leading player in the areas of Cardiovascular and Central Nervous Systems, having achieved significant presence in segments of Nephrology, Oncology, Pulmonology, Gynecology and Pediatric treatments.The company operates in two key business segments - Branded Generics (BGx) and Generics (Gx). Each segment plays a pivotal role in its growth strategy, catering to diverse therapeutic needs across different regions.

Who are the competitors of Torrent Pharma?

Torrent Pharma major competitors are Cipla, Dr. Reddy's Labs., Zydus Lifesciences, Lupin, Mankind Pharma, Aurobindo Pharma, Alkem Laboratories.
Market Cap of Torrent Pharma is ₹1,52,915 Crs.
While the median market cap of its peers are ₹1,07,091 Crs.

Is Torrent Pharma financially stable compared to its competitors?

Torrent Pharma seems to be less financially stable compared to its competitors.
Altman Z score of Torrent Pharma is 3.46 and is ranked 8 out of its 8 competitors.

View FAQ's On Shareprice

Cash Flow Machines

Actual Cash profits are more important than accounting profits. List of companies spitting out cash profits

Run Query

Company Filing

	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release	Feb May	May Jul Nov	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep	Mar Jun Sep Dec	Dec	Mar Jun Sep	Sep Dec	Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Dec
Investor Presentation	Feb May	May Jun Jul Nov	Mar Jun Jul Sep Dec	Mar Jun Sep Dec	May Jun Jul Sep Dec	Jan Mar Jun Sep Dec	Jun Sep Dec	Mar Jun Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec
Conference Call	Feb May	Mar Jun Nov	Mar Jun Sep Dec	Mar Jun Sep	Mar Sep Dec	Mar Jun Sep	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep Dec	Mar Jun Sep Dec	Mar Jun Sep Dec	Jun Sep Dec
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Torrent Pharmaceuticals Ltd.

Interview With Dilip Sanghvi, Managing Director - Sun Pharmaceutical Samir Mehta, Chairman - Torrent Pharma - Flame University

View the discussion on ValuePickr

Pharmaceuticals

GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Nutraceuticals- Industry Overview - Value Educator

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Pharma Compliance In-Depth - Amit Rajan

Deep Dive into Pharma Sector - Omkara Capital

How The Pharma Industry Works - PPFAS

Ideas Dashboard

Results

Timeline

Watchlist

Portfolio

Alerts

Stock Screener

Market

Raw Material

Torrent Pharmaceuticals Ltd.

Torrent Pharmaceuticals Ltd.

Key Ratios

About

Timeline

Company Timeline

Custom financial statement

Forensics

9 Yes

2 Neutral

6 No

0 No Data

Accounting & Shareholding

Contingent Liabilities

Depreciation Effect

Other Income

Pledge

Retail Holding

Promoter Holding

Revenue Recognition

Price & Performance

ROE

Working Capital

Debt

Balance Sheet Strength

Capex vs ROCE

Current vs Historic Valuation

Share price

Sales Growth

Margin Stability

ROCE Strength

Market Share

Revenue mix

Product Wise Break-Up

UNLOCK PREMIUM

Location Wise Break-Up

UNLOCK PREMIUM

Therapeutic Area Break-Up

UNLOCK PREMIUM

Acute vs Chronic

UNLOCK PREMIUM

Asset Break-Up

UNLOCK PREMIUM

Operational Metrics

Peer Comparison

Brands

Corporate Actions

Suppliers

FAQs on Torrent Pharmaceuticals Ltd. Business

What does Torrent Pharma do?

Who are the competitors of Torrent Pharma?

Is Torrent Pharma financially stable compared to its competitors?

Similar Companies

Company Filing

Discussions & Analysis

SIGN UP FOR FREE